The adjuvanttctty of a sulfohpopolysaccharMe (SLP) mcorporated mto a squalane-mwater emulslon (SLP/S/W) was compared wtth that of a mmeral od-m-water (0/W 362 and 128for ) 69 and 49for tPRV, and 23 and 7 
The most common types of adjuvants used in vaccines for domestic food animals are still emulsions of either the oil-in-water or water-in-oil type, based on oll of mineral origin In general, these adjuvants exhibit strong activity with a wide range of antigens but, possibly owing to limited biodegradability and bIocompatlbihty, their application is often accompanied with certain side-effects and risks Parenteral administration of mineral oll emulsions into animals frequently provokes reactions at the site of injection of which the severity and duration depend on the nature and concentration of the od and physlcochemlcal characteristics of the emulsions 1 Studies at the site of injection 2'3 and in other anatomic compartments 4 for a long period of time As a consequence of this persistence, It cannot be excluded that consumers of food of animal origin are exposed to oil residues and although detrimental effects of such residues are not exhaustively documented, they might introduce certain risks to human health In addition, there exist also risks to veterinary surgeons or animal handlers of accidental autolnjectlon For these reasons, replacement of the mineral oll components while retaining adjuvantlclty but reducing risks is very desirable Several attempts have been described and a few veterinary vaccines are at present on the market supplemented with novel adjuvants e g vitamin E, polyacrylate resins (Carbopol, of B F Goodrich), acetylated polymannose (Acemannan, Carrlngton Labs) and avndlne Emulsions of oils of vegetable origin such as peanut, olive, sesame oil etc 5-a or of animal origin, e g squalane and squalene 9, have also been investigated but activity was almost always insufficient compared to mineral oll
In an accompanying paper 1° we have described the adjuvantlclty of a synthetic, high-molecular-weight polysucrose derlvatized with fatty acid esters and sulfate 
Animals
Pigs of 8-10 weeks of age were screened for the presence of antibodies agamst the viral antigens in question and animals with detectable antibody tltres were excluded
Vaccines
Antigens were prepared as described previously ~° The following doses of antigen (corresponding to 1 ml of antigen solution) were injected 4 4 #g influenza virus A/Swine+40#g MRC-11+20#g X-79 (1Flu3), 108 TCIDso inactivated pseudorables virus (IPRV), 10 s TCIDso live pseudorables virus (PRV), and 105 TCIDso macttvated porcine parvovlrus (1PPV) Adjuvants tested have been described elsewhere ~° Vaccines were obtained by either mixing 1 volume of anttgen with 1 volume adjuvant solution or resuspending lyophlhzed virus (live PRV) in distilled water or adjuvant solution diluted with an equal volume of distilled water
Vaccination
Groups of at least five pigs were injected twice intramuscularly (i m ) with 2 0 ml vaccine per animal at weeks 0 and 3 and blood was collected 2 or 3 weeks after the second Immunization
Antibody titres against influenza and pseudorabies virus
Anti-influenza and antt-pseudorables virus antibody tltres were measured as described previously ~°
Antibody titres against PPV
Serum samples were inactivated by mcubatlng for 30 mln at 56°C and pretreated with 3 volumes of kaolin suspension (ICN/Flow Labs, Irvlne, UK) and twice with 1 volume of a suspension of 50% gumea-pig red blood cells (GpRBC) in PBS Then, 50/4 of the serum samples were diluted m PBS in 96-well plates and 50 #1 of a vtrus suspension containing 8 HA PPV were added to the serum dtlutions After incubation for 45 mln at room temperature, 50 #1 of a 0 6% GpRBC suspension in PBS were added After 1-2 h, agglutination was detected and the reciprocal value of the htghest serum dilution demonstrating HI was considered to be the tltre
Virus excretion upon challenge with virulent PRV
Virus excreted after challenge with virulent PRV was determined by the method described by VannIer et al ~ Briefly, nasal swabs were taken dally from individual pigs from before challenge to 12 days postchallenge The swabs were weighed before and after sampling and soaked in 2 ml of culture medium and stored at -70°C for a maxtmum of 14 days Samples of 100 #1 of these culture media were taken and the numbers of plaqueforming units were determined The means ( + s e m ) were calculated of the 10-log of TCIDso on PD 5 cells per gram of mucus
Statistical analysis
Analysis of samples was performed by standardized tests and criteria for vahdlty have been described before 1° Student's t test was carried out to analyse stattsttcal significance of the results and p>005 was considered to be significant
RESULTS

Effect of SLP/S/W on the antibody response against iFlu3 in pigs
In five independent experiments, groups of pigs were immunized twtce with a combination of three Influenza virus strains plus different adjuvants, and blood samples were taken 3 weeks after the second vaccination Antibody titres achieved by either SLP/S/W, S/W or SLP were compared with those of antigen alone or antigen plus O/W (Ftgure 1)
In general, differences in titres against the three virus strains were seen between the indIvtdual experiments and responses against A/Swine were lower than those against the two other strains The mean factors of increase in responses to A/Swine, MRC-11 and X-79 observed varied 
Non-mmeral otl adluvant for vetermary vaccines L A Th Hflgers et al
Effect of SLP/S/W and O/W on virus excretion upon challenge
Groups of five pigs were vaccinated twice with a time Interval of 3 weeks, 5 weeks after the second vaccination, they were challenged with virulent PRV Two out of five non-vaccinated control animals died shortly after challenge All animals that received live PRV vaccine with or without adjuvant survived the challenge Virus tltres in tonsillar swabs were monitored over 14 (Table 3 ) Before immunization, no antibodies were detected After the first rejection, significant antibody tatres in serum were observed and both adjuvants appeared to be equally effective Responses increased upon the second injection with vaccine and SLP/S/W evoked a significantly higher tltre than O/W DISCUSSION In the hterature, many adjuvants have been described but most data have been obtained from studies in laboratory animals Efficacy of these experimental adjuvants in target animals is often disappointing In this paper we described the adjuvant activity of a novel formulation in the target animal species, a e pigs It is the outcome of an extensive research programme on non-mineral o11 adjuvants for veterinary purposes which included the screening of a large number of different compounds and formulations in mace or guinea-pigs and subsequent testmg of promising substances m target animal species In laboratory animals, several experimental adjuvants displayed distinct activity with the different types of antigens tested and only those which exhibited strong overall activity were tested in target species Among several others, an experimental formulation comprising a synthetic polysucrose derlvatazed with sulfate and hpld groups and incorporated into a squalane-an-water emulsion (SLP/S/W) appeared to exert strong adjuvantlcaty against a protein, a hapten carrier, and two viral antigens 1° Subsequent testing in pigs revealed that this SLP/S/W was sagmficantly more effective than several other experimental formulations (data not shown) As reported here, it enhanced antibody responses against three inactivated Influenza viruses, inactivated and live PRV, and against inactivated PPV Relative to negative controls which received antigen without adjuvant, anti-influenza antibody tltres were increased 315-to 478-fold Humoral responses against 1PRV and lave PRV were increased 69-and 23-fold, respectively As compared with the commercially applied O/W adjuvant, SLP/S/W was about three-to fourfold more effecnve an stimulating responses against the three influenza virus strains tested, hve PRV and aPPV, and equally effective in enhancing responses against IPRV The two constituent substances SLP and S/W also augmented responses against the viral antigens but the combination thereof demonstrated synergistic activity Similar beneficial interaction has been observed in mice and guinea-pigs 1° In principle, adjuvants are used to compensate for lack of potency of lnacnvated antigens as compared with their live counterparts Experiments with inactivated and live PRV revealed that ~mmune responses against both types of anngens can be enhanced upon addlnon of an adjuvant The stlmulatory effect of adjuvants on the immunity induced by live antigens has been reported previously 11 12 and has resulted an improved vaccines against Aujeszky disease Considerable differences were seen an levels of antl-PRV antibody responses against either reactivated or hve PRV Live PRV vaccine without adjuvant evoked anttbody levels that were comparable with those obtained by 1PRV plus adjuvant The possibility of increasing responses against live PRV by an adjuvant suggests that the immune system may not always react maximally to a live virus antigen Increased antibody tltres against live PRV upon vaccination corresponded closely to decreased titres of virus in nasal fluid at different intervals after challenge with virulent PRV A comparable, inverse relationship between humoral response and protection against virus excretion has been described by other investigators TM 13 The role of circulating antibodies In protection against virus excretion can be deduced from investigation with inactivated antigen administered parenterally as this route of immunization is thought to be incapable of inducing significant levels of either cell-mediated or local immunity Intramuscular immunization of animals with purified protein gp50 of PRV evoked neutralizing antibodies in serum and reduced virus excretion upon challenge ~ 3
Adjuvanticity of mineral oil emulsions is believed to be at least partially related to the persistence of oil components in the host, as emulsions of oil of either vegetable or animal origin are considerably less effective Additional active substances such as microbial glycohpids 14, synthetic block polymers of polyoxyethylene and polyoxypropylene with or without microbial products 15, avridme 16 or SLP, can compensate for low activity of the biodegradable oil emulsions
The SLP/S/W adjuvant formulation was developed to replace mineral oil-based adjuvants, thereby reducing toxic side-effects of vaccination Vaccines at present used in pigs often contain 25-60% mineral oil Concentrations of SLP and squalane used in the experimental vaccines are considerably lower, namely 0 5 and 5 % respectively Furthermore, low toxicity and high biocompatlbihty of squalane is expected since squalane is a normal constituent of animal tissue and as such is present In low concentrations in most animal species Next to squalene, it is the most common hydrocarbon in human sebum ~7 As a consequence, plain emulsions of squalane are considered to be biodegradable and to be of low or no risk to consumers of food containing residues thereof Toxicological studies on squalane affirmed relative safety ~v Squalane has been used in cosmetics in high concentrations for more than 25 years and in pharmaceuticals as a carrier for lipid drugs 1T The SLP used in this novel adjuvant formulation is a new chemical entity and besides lmmunostimulatory activity, biological effects are not known As it is built up of naturally occurring compounds, i e sucrose, fatty acids and sulfate, low toxicity of SLP and degradation products might be expected The sugar backbone, Ficoll-400, is a relatively inert copolymer of sucrose and epichlorohydrin and degradation of SLP m wvo is considered to include cleavage of lipid and sulfate-ester bonds rather than breakdown of the polymer Such a degradation will yield fatty acids, sulfate and polysucrose Taking into account (1) low doses of active components, (2) blocompatlblhty of squalane, (3) chemical composition and the most likely route of degradation of SLP, and (4) very low absorption rate of a polysucrose analogue with a 25-fold lower molecular weight by the gastrointestinal tract 18'~9, SLP/S/W is thought to be of low risk to the consumers of food made from animals treated with this adjuvant In summary, the novel SLP/S/W is an effective adjuvant for humoral responses against influenza virus strains A/Swine, MRC-11 and X-79, for inactivated and live PRV and for 1PPV, and the two active components (i e SLP and S/W) interact synergistically Despite lower doses of active substances and blocompatlbihty of the oil component, it is more effective overall than the O/W adjuvant currently used As far as we know, this is the first time that a non-mineral oil adjuvant has been proven to have such a high efficacy in pigs and thus it is a potential candidate for use in porcine vaccines
